Laboratorios Farmaceuticos Rovi (ROVI) Q2 2024 earnings summary

Executive summary

• Operating revenue for H1 2024 fell 14% year-over-year to €329.3M, mainly due to a 31% drop in CDMO sales and lower COVID-19 vaccine manufacturing revenues, partially offset by strong Okedi® sales (up 141% to €12.5M) and Neparvis® (up 13% to €25.0M).

• Specialty pharma business showed resilience, with sales up 1% to €210.5M, driven by Okedi®, Neparvis®, Bemiparin, and hospital products.

• Net profit declined 33% to €44.3M, EBITDA dropped 28% to €69.9M, and EBIT fell 34% to €56.5M.

• Gross margin improved by 2.8pp to 59.4%, mainly due to a favorable product mix and reduced low-margin CDMO activities.

• 2024 is described as a transition year, with significant investments and new agreements (e.g., prefilled syringes) laying the foundation for future growth.

Financial highlights

• EBITDA fell 28% to €69.9M, with EBITDA margin down 4.3pp to 21.2%.

• Net profit dropped 33% to €44.3M.

• Gross margin improved by 2.8pp to 59.4%, driven by higher-margin products.

• Capex totaled €18.7M, mainly for facility expansion and ISM industrialization.

• Free cash flow was €11.2M, down 68% year-over-year; net debt rose to €74.7M as of June 30, 2024.

Outlook and guidance

• Full-year 2024 operating revenue expected to decrease by a mid-single-digit percentage compared to 2023.

• Guidance factors in uncertainties around COVID-19 vaccine demand, timing of new CDMO contracts, and partner orders.

• Expansion of production capacity and new agreements (e.g., prefilled syringes) expected to drive future growth.